Korea's Celltrion Gains European Foothold With Latvian Clinical Trial Approval For Herceptin Biosimilar
This article was originally published in The Pink Sheet Daily
Looking ahead to the expiration of Roche's patent rights for trastuzumab in 2019, Korean firm will start trials in Korea soon and in Latvia later this year.
You may also be interested in...
SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News
SEOUL - While South Korea's FDA is getting ready to release its initial version of registration guidelines for biosimilars, the Ministry for Knowledge Economy said it would use public funds to help local pharma and biotech companies to compete in the biosimilar arena